Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: Similar outcomes belie distinctive biologic differences Journal Article


Authors: Soslow, R. A.; Bissonnette, J. P.; Wilton, A.; Ferguson, S. E.; Alektiar, K. M.; Duska, L. R.; Oliva, E.
Article Title: Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: Similar outcomes belie distinctive biologic differences
Abstract: The clinical and histopathologic features of 187 high-grade endometrial cancers [FIGO grade 3 endometrioid (EC-3), serous (SC), and clear cell (CC)] were studied to determine whether clinicopathologic differences between these various histologic subtypes existed. The study group consisted of 89 EC-3s, 61 SCs, and 37 CCs. Treatment regimens were individualized. SCs and CCs were significantly more likely than EC-3s to occur in patients older than 65 years (P=0.03), and SCs tended to occur more frequently in patients of African descent than EC-3s and CCs (P=0.07), although this was not statistically significant. EC-3s had the highest rate of associated endometrial hyperplasia (P=0.05). SCs were most likely to have high-stage disease at presentation (≥stage IIB; P=0.01), with peritoneal dissemination at diagnosis being much more common compared with EC-3s and CCs (P=0.004). Median follow-up was 39 months, and median overall survival was 47 months. Five-year survivals were 45% (EC-3), 36% (SC), and 50% (CC)-differences that were not statistically significant. In contrast, the impact of stage on survival was significant (P<0.001). Among all other factors evaluated, only age greater than 65 years was a negative predictor (risk ratio, 2.23; P<0.001), whereas a family history of cancer reduced the risk of death when controlling for stage (risk ratio, 0.54; P=0.005). When controlling for stage, race, reproductive history, personal history of cancer, histologic subtype, depth of myometrial invasion, lymphovascular invasion, presence of an endometrial polyp, presence of hyperplasia, or staging adequacy did not affect prognosis. High-grade endometrial cancers of different histologic subtypes treated in an individualized manner are associated with similar clinical outcomes, but differences in age at presentation, race distribution, association with hyperplasia, stage, and sites of tumor dissemination support the idea that these represent distinct disease entities as defined by traditional histopathologic classification of endometrial cancers. © 2007 Lippincott Williams & Wilkins, Inc.
Keywords: cancer survival; human tissue; aged; middle aged; major clinical study; overall survival; histopathology; cisplatin; doxorubicin; cancer combination chemotherapy; cancer risk; monotherapy; treatment planning; paclitaxel; cancer adjuvant therapy; cancer radiotherapy; cancer staging; outcome assessment; follow up; endometrioid carcinoma; endometrium carcinoma; endometrial neoplasms; neoplasm staging; cancer grading; adenocarcinoma; disease association; tumor localization; cyclophosphamide; prediction; cancer invasion; lymph vessel; statistical analysis; prognostic factors; outcome; age distribution; clear cell carcinoma; adenocarcinoma, clear cell; cystadenocarcinoma, serous; new york; race difference; carcinoma, endometrioid; serous carcinoma; massachusetts; ethnic groups; endometrium hyperplasia; grade 3 endometrioid carcinoma; high-grade endometrial carcinoma; endometrium polyp
Journal Title: American Journal of Surgical Pathology
Volume: 31
Issue: 7
ISSN: 0147-5185
Publisher: Lippincott Williams & Wilkins  
Date Published: 2007-07-01
Start Page: 979
End Page: 987
Language: English
DOI: 10.1097/PAS.0b013e31802ee494
PUBMED: 17592263
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 27" - "Export Date: 17 November 2011" - "CODEN: AJSPD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew Wilton
    27 Wilton
  2. Kaled M Alektiar
    333 Alektiar
  3. Robert Soslow
    793 Soslow